Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

1998 • 19,638 citations

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

1998 • 8,603 citations

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

1998 • 7,971 citations

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

1998 • 4,159 citations

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

2006 • 2,850 citations

Metformin and reduced risk of cancer in diabetic patients

2005 • 2,278 citations

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

2009 • 1,337 citations

International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use

2010 • 1,239 citations

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

2009 • 1,098 citations

Metformin Is an AMP Kinase–Dependent Growth Inhibitor for Breast Cancer Cells

2006 • 1,038 citations

TIME-DEPENDENT COVARIATES IN THE COX PROPORTIONAL-HAZARDS REGRESSION MODEL

1999 • 912 citations

Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin

2006 • 910 citations

The Role of Obesity and Related Metabolic Disturbances in Cancers of the Colon, Prostate, and Pancreas

2007 • 540 citations

[Commentary to the article: Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43].

2007 • 249 citations

Contra‐indications to metformin therapy are largely disregarded

1999 • 127 citations